Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Rabeprazole. |
| Dabrafenib | The serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Rabeprazole. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Rabeprazole. |
| Amphetamine | Rabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Atazanavir | Rabeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Rabeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Rabeprazole. |
| Dabigatran etexilate | Rabeprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Rabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Rabeprazole can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dextroamphetamine | Rabeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Erlotinib | Rabeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluconazole | The metabolism of Rabeprazole can be decreased when combined with Fluconazole. |
| Gefitinib | Rabeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Rabeprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Rabeprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Rabeprazole can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | The excretion of Methotrexate can be decreased when combined with Rabeprazole. |
| Methylphenidate | Rabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexmethylphenidate | Rabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Nelfinavir | The serum concentration of Nelfinavir can be decreased when it is combined with Rabeprazole. |
| Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole. |
| Pazopanib | Rabeprazole can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Posaconazole | Rabeprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Rabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rilpivirine | Rabeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Rabeprazole can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Rabeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | The serum concentration of Saquinavir can be increased when it is combined with Rabeprazole. |
| Voriconazole | The metabolism of Rabeprazole can be decreased when combined with Voriconazole. |
| Luliconazole | The serum concentration of Rabeprazole can be increased when it is combined with Luliconazole. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Rabeprazole. |
| Fentanyl | Fentanyl may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Rabeprazole. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Rabeprazole. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Rabeprazole. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Rabeprazole. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Rabeprazole. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Rabeprazole. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Rabeprazole. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Rabeprazole. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Rabeprazole. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Rabeprazole. |
| Levothyroxine | Rabeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Rabeprazole. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Rabeprazole. |
| (R)-warfarin | The serum concentration of (R)-warfarin can be increased when it is combined with Rabeprazole. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Rabeprazole. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Rabeprazole. |
| (S)-Warfarin | The serum concentration of (S)-Warfarin can be increased when it is combined with Rabeprazole. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Rabeprazole. |
| Clopidogrel | The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Rabeprazole. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Rabeprazole. |
| Captopril | Rabeprazole can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Rabeprazole. |
| Rifampin | Rabeprazole can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Rabeprazole may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Rabeprazole. |
| Mesalazine | Rabeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Rabeprazole. |
| Alendronic acid | The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole. |
| Ibandronate | The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole. |
| Clodronic acid | The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Rabeprazole. |
| Etidronic acid | The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Rabeprazole. |
| Incadronic acid | The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Rabeprazole. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Rabeprazole. |
| Ketoconazole | Rabeprazole can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lumacaftor | The serum concentration of Rabeprazole can be decreased when it is combined with Lumacaftor. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Rabeprazole. |
| Fluvoxamine | The metabolism of Rabeprazole can be decreased when combined with Fluvoxamine. |
| Ticlopidine | The metabolism of Rabeprazole can be decreased when combined with Ticlopidine. |
| Chloramphenicol | The metabolism of Rabeprazole can be decreased when combined with Chloramphenicol. |
| Lansoprazole | The metabolism of Rabeprazole can be decreased when combined with Lansoprazole. |
| Fluoxetine | The metabolism of Rabeprazole can be decreased when combined with Fluoxetine. |
| Zafirlukast | The metabolism of Rabeprazole can be decreased when combined with Zafirlukast. |
| Isoniazid | The metabolism of Rabeprazole can be decreased when combined with Isoniazid. |
| Miconazole | The metabolism of Rabeprazole can be decreased when combined with Miconazole. |
| Gemfibrozil | The metabolism of Rabeprazole can be decreased when combined with Gemfibrozil. |
| Stiripentol | The metabolism of Rabeprazole can be decreased when combined with Stiripentol. |
| Eslicarbazepine acetate | The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine acetate. |
| Efavirenz | The metabolism of Rabeprazole can be decreased when combined with Efavirenz. |
| Prussian blue | Rabeprazole can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Rabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Rabeprazole can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Rabeprazole can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Rabeprazole can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Rabeprazole can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Rabeprazole can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Rabeprazole can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Rabeprazole can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Rabeprazole can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Rabeprazole can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Rabeprazole can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Rabeprazole can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Rabeprazole can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Rabeprazole can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Rabeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |